Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Buda

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|May 17, 2012
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortiumDaniele Campa, Alessandro Martino, Juan Sainz, et al.
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)]Alberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
Frontiers in Oncology|December 22, 2018
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid LeukemiaSara Galimberti, Susanna Grassi, Claudia Baratè, et al.
British Journal of Haematology|March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MMAlessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Annals of Hematology|August 21, 2024
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapyVanda Strafella, Immacolata Attolico, Paola Carluccio, et al.
American Journal of Hematology|February 6, 2015
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemiasLuana Fianchi, Livio Pagano, Alfonso Piciocchi, et al.
Oncotarget|July 21, 2016
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysisRafael Ríos-Tamayo, Carmen Belén Lupiañez, Daniele Campa, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 14, 2014
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene eraAlessandro Martino, Daniele Campa, Artur Jurczyszyn, et al.
British Journal of Haematology|August 7, 2018
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patientsAngelica Macauda, Eleonora Castelli, Gabriele Buda, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|May 17, 2012
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortiumDaniele Campa, Alessandro Martino, Juan Sainz, et al.
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)]Alberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
Frontiers in Oncology|December 22, 2018
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid LeukemiaSara Galimberti, Susanna Grassi, Claudia Baratè, et al.
British Journal of Haematology|March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MMAlessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Annals of Hematology|August 21, 2024
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapyVanda Strafella, Immacolata Attolico, Paola Carluccio, et al.
American Journal of Hematology|February 6, 2015
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemiasLuana Fianchi, Livio Pagano, Alfonso Piciocchi, et al.
Oncotarget|July 21, 2016
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysisRafael Ríos-Tamayo, Carmen Belén Lupiañez, Daniele Campa, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 14, 2014
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene eraAlessandro Martino, Daniele Campa, Artur Jurczyszyn, et al.
British Journal of Haematology|August 7, 2018
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patientsAngelica Macauda, Eleonora Castelli, Gabriele Buda, et al.
Pageof 14